Literature DB >> 21156659

The Heart Failure Revascularisation Trial (HEART).

John G F Cleland1, Melanie Calvert, Nick Freemantle, Yvonne Arrow, Stephen G Ball, Robert S Bonser, Sudipta Chattopadhyay, Michael S Norell, Dudley J Pennell, Roxy Senior.   

Abstract

AIMS: Revascularization is frequently advocated to improve ventricular function and prognosis for patients with heart failure due to coronary artery disease, especially when there is evidence of extensive myocardial viability. METHODS AND
RESULTS: Patients with heart failure, coronary artery disease, and a left ventricular (LV) ejection fraction < 35%, who had a substantial volume of viable myocardium with contractile dysfunction assessed by any standard imaging technique, were randomly assigned to a strategy of conservative management vs. angiography with the intent of percutaneous or surgical revascularization. Patients requiring revascularization for angina or too frail for surgery were excluded. Only 138 of the planned 800 patients were enrolled because of withdrawal of funding due to slow recruitment. Also, a larger trial (The Surgical Treatment for Ischemic Heart Failure Trial) addressing a similar question became available, which investigators were encouraged to join. Of 69 patients assigned to the invasive strategy, 6 refused angiography, 2 died as a result of the diagnostic procedure, 14 were considered unsuitable for revascularization, 2 refused surgery, and 45 had revascularization. After a median follow-up of 59 (inter-quartile range: 33-63) months, there were 51 (37%) deaths; 25 (37%) in those assigned to the conservative strategy, and 26 (38%) in those assigned to the invasive strategy, 13 (29%) of whom had been revascularized.
CONCLUSION: A conservative management strategy may not be inferior to one of coronary arteriography with the intent to revascularize in patients with heart failure, LV systolic dysfunction, and extensive myocardial viability. However, this study was underpowered and, further, larger trials are required to settle this issue. Clinical trials Registration No: ISRCTN86284615.

Entities:  

Mesh:

Year:  2010        PMID: 21156659     DOI: 10.1093/eurjhf/hfq230

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  52 in total

Review 1.  SPECT and PET in ischemic heart failure.

Authors:  George Angelidis; Gregory Giamouzis; Georgios Karagiannis; Javed Butler; Ioannis Tsougos; Varvara Valotassiou; George Giannakoulas; Nikolaos Dimakopoulos; Andrew Xanthopoulos; John Skoularigis; Filippos Triposkiadis; Panagiotis Georgoulias
Journal:  Heart Fail Rev       Date:  2017-03       Impact factor: 4.214

Review 2.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

3.  Myocardial viability testing: still viable after stich?

Authors:  Robert O Bonow; Thomas A Holly
Journal:  J Nucl Cardiol       Date:  2011-12       Impact factor: 5.952

4.  Interventional therapies in ischemic ventricular dysfunction: facts and versions!

Authors:  Paulo Cury Rezende; Diogo Freitas Cardoso de Azevedo; Whady Hueb
Journal:  Ann Transl Med       Date:  2016-10

Review 5.  Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging Guidelines: Instrumentation, Acquisition, Processing, and Interpretation.

Authors:  Sharmila Dorbala; Karthik Ananthasubramaniam; Ian S Armstrong; Panithaya Chareonthaitawee; E Gordon DePuey; Andrew J Einstein; Robert J Gropler; Thomas A Holly; John J Mahmarian; Mi-Ae Park; Donna M Polk; Raymond Russell; Piotr J Slomka; Randall C Thompson; R Glenn Wells
Journal:  J Nucl Cardiol       Date:  2018-10       Impact factor: 5.952

Review 6.  Is ischemia the most powerful indicator of myocardial viability?

Authors:  Jamshid Shirani
Journal:  Curr Cardiol Rep       Date:  2013-05       Impact factor: 2.931

Review 7.  Myocardial Viability and Revascularization: Current Understanding and Future Directions.

Authors:  Pavan Patel; Alexander Ivanov; Kumudha Ramasubbu
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

8.  Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit?: Myocardial imaging should not exclude patients with ischemic heart failure from coronary revascularization.

Authors:  Eric J Velazquez
Journal:  Circ Cardiovasc Imaging       Date:  2012-03       Impact factor: 7.792

9.  Relationship of myocardial hibernation, scar, and angiographic collateral flow in ischemic cardiomyopathy with coronary chronic total occlusion.

Authors:  Li Wang; Min-Jie Lu; Lei Feng; Juan Wang; Wei Fang; Zuo-Xiang He; Ke-Fei Dou; Shi-Hua Zhao; Min-Fu Yang
Journal:  J Nucl Cardiol       Date:  2018-03-07       Impact factor: 5.952

10.  Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial.

Authors:  Robert J Mentz; Bradley D Allen; Mary J Kwasny; Marvin A Konstam; James E Udelson; Andrew P Ambrosy; Angela J Fought; Muthiah Vaduganathan; Christopher M O'Connor; Faiez Zannad; Aldo P Maggioni; Karl Swedberg; Robert O Bonow; Mihai Gheorghiade
Journal:  Eur J Heart Fail       Date:  2012-09-11       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.